{
  "nctId": "NCT03405714",
  "briefTitle": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy",
  "officialTitle": "A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month < 16 Years of Age With Epilepsy",
  "protocolDocument": {
    "nctId": "NCT03405714",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2019-06-19",
    "uploadDate": "2021-05-03T08:04",
    "size": 1774888,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03405714/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 50,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-06-01",
    "completionDate": "2020-11-04",
    "primaryCompletionDate": "2020-11-04",
    "firstSubmitDate": "2018-01-12",
    "firstPostDate": "2018-01-23"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Male or female from \\>= 1 month to \\< 16 years of age. For subjects who are \\< 1 year from birth and who were preterm infants, the corrected gestational age should be used for this entry requirement\n* Weight \\>= 3 kg (6.6 lbs)\n* Diagnosis of epilepsy\n* Acceptable candidate for venipuncture and intravenous (iv) infusion\n* Treatment with \\>=1 anti epileptic drug (AED; including BRV) without a change of dose regimen for at least 7 days prior to Screening\n* No treatment with vagus nerve stimulation (VNS), OR the subject is being treated with VNS and the settings have been constant for \\>=7 days prior to Screening\n* For female subjects: not of childbearing potential, OR of childbearing potential and not sexually active/negative pregnancy test, OR of childbearing potential and sexually active/negative pregnancy test/uses medically acceptable contraceptive methods\n\nExclusion Criteria:\n\n* Subject has previously received iv Brivaracetam (BRV) in this study\n* Subject is being treated with BRV at a dose \\>5mg/kg/day (rounded) or \\>200mg/day for subjects with body weights \\>40kg\n* Subject requires or is likely to require a change in concomitant antiepileptic drug(s) (AED\\[s\\]), dose of concomitant AED(s), or formulation of AED(s) during the 7 days prior to the intravenous (iv) pharmacokinetic (PK) Period\n* Subject is likely, in the opinion of the Investigator, to require rescue medication during the Initiating Oral BRV (IOB) Treatment or iv PK Periods\n* Subject has experienced generalized convulsive status epilepticus in the 28 days prior to Screening or during the Screening Period",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "1 Month",
    "maximumAge": "16 Years",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "At <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "At 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "At 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus",
        "description": "Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.",
        "timeFrame": "Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)"
      },
      {
        "measure": "Number of Participants With Adverse Events (AEs)",
        "description": "An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.",
        "timeFrame": "From Screening until last visit (up to Day 68)"
      },
      {
        "measure": "Number of Participant Withdrawals Due to Adverse Events",
        "description": "An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.",
        "timeFrame": "From Screening until last visit (up to Day 68)"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 29,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 29
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:48.208Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}